Company intelligence / Profile preview

Oak Bay Biosciences

Victoria, British Columbia, Canadaca.linkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Oak Bay Biosciences is developing a proprietary small molecule therapy aimed at halting the progression of Stargardt disease, an inherited form of blindness. Their lead candidate has shown promising preclinical results, including high efficacy (>90% in preventing retinal cell death), low dosage requirements, and fewer side effects compared to other treatments under development. The company is currently raising funds to advance into clinical proof-of-concept trials.

Therapeutic areas: Ophthalmology
Modalities: Small molecules (lead molecule for Stargardt disease)
Industry: Biotech

Partnerships

Collaborations with world-class science, medical, and technical experts are mentioned but not named specifically.

Beyond the preview

Go deeper on Oak Bay Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oak Bay Biosciences.

Explore the full profile